175 related articles for article (PubMed ID: 36935014)
1. Management of cutaneous lupus erythematosus with Janus kinase inhibitor therapy: An evidence-based review.
Abduelmula A; Sood S; Mufti A; Hinek A; Yeung J
J Am Acad Dermatol; 2023 Jul; 89(1):130-131. PubMed ID: 36935014
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of Janus kinase inhibitors in systemic and cutaneous lupus erythematosus: A systematic review and meta-analysis.
Ma L; Peng L; Zhao J; Bai W; Jiang N; Zhang S; Wu C; Wang L; Xu D; Leng X; Wang Q; Zhang W; Zhao Y; Tian X; Li M; Zeng X
Autoimmun Rev; 2023 Dec; 22(12):103440. PubMed ID: 37678618
[TBL] [Abstract][Full Text] [Related]
3. Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease.
Huang MY; Armstrong AW
Indian J Dermatol Venereol Leprol; 2023 [SEASON]; 90(1):30-40. PubMed ID: 38031699
[TBL] [Abstract][Full Text] [Related]
4. Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus?
Richter P; Cardoneanu A; Burlui AM; Macovei LA; Bratoiu I; Buliga-Finis ON; Rezus E
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233087
[TBL] [Abstract][Full Text] [Related]
5. A novel JAK/ROCK inhibitor, CPL409116, demonstrates potent efficacy in the mouse model of systemic lupus erythematosus.
Dulak-Lis M; Bujak A; Gala K; Banach M; Kędzierska U; Miszkiel J; Hucz-Kalitowska J; Mroczkiewicz M; Stypik B; Szymczak K; Gunerka P; Dubiel K; Zygmunt BM; Wieczorek M; Pieczykolan JS
J Pharmacol Sci; 2021 Apr; 145(4):340-348. PubMed ID: 33712286
[TBL] [Abstract][Full Text] [Related]
6. Refractory alopecia in lupus treated with tofacitinib - a case-based review.
Sarkar R; Mv P; Hinduja N; Sethy M; Kar H; Ahmed S
Clin Rheumatol; 2023 Aug; 42(8):2237-2241. PubMed ID: 37188961
[TBL] [Abstract][Full Text] [Related]
7. Pathological relevance and treatment perspective of JAK targeting in systemic lupus erythematosus.
Nakayamada S; Tanaka Y
Expert Rev Clin Immunol; 2022 Mar; 18(3):245-252. PubMed ID: 35138987
[TBL] [Abstract][Full Text] [Related]
8. JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus.
Klaeschen AS; Wolf D; Brossart P; Bieber T; Wenzel J
Exp Dermatol; 2017 Aug; 26(8):728-730. PubMed ID: 27892610
[TBL] [Abstract][Full Text] [Related]
9. Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent.
Alunno A; Padjen I; Fanouriakis A; Boumpas DT
Cells; 2019 Aug; 8(8):. PubMed ID: 31443172
[TBL] [Abstract][Full Text] [Related]
10. The Jakinibs in systemic lupus erythematosus: progress and prospects.
Mok CC
Expert Opin Investig Drugs; 2019 Jan; 28(1):85-92. PubMed ID: 30462559
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Clinical Response to Janus Kinase Inhibition in Patients With Familial Chilblain Lupus and TREX1 Mutation.
Zimmermann N; Wolf C; Schwenke R; Lüth A; Schmidt F; Engel K; Lee-Kirsch MA; Günther C
JAMA Dermatol; 2019 Mar; 155(3):342-346. PubMed ID: 30673078
[TBL] [Abstract][Full Text] [Related]
12. Janus kinases inhibitors for treating patients with rhupus.
Garufi C; Mancuso S; Spinelli FR; Truglia S; Ceccarelli F; Alessandri C; Conti F
Joint Bone Spine; 2020 Dec; 87(6):673-674. PubMed ID: 32534202
[No Abstract] [Full Text] [Related]
13. Efficacy of JAK1/2 inhibition in the treatment of chilblain lupus due to TREX1 deficiency.
Briand C; Frémond ML; Bessis D; Carbasse A; Rice GI; Bondet V; Duffy D; Chatenoud L; Blanche S; Crow YJ; Neven B
Ann Rheum Dis; 2019 Mar; 78(3):431-433. PubMed ID: 30282666
[No Abstract] [Full Text] [Related]
14. Biological therapies in the treatment of cutaneous lupus erythematosus.
Presto JK; Hejazi EZ; Werth VP
Lupus; 2017 Feb; 26(2):115-118. PubMed ID: 27687023
[TBL] [Abstract][Full Text] [Related]
15. JAK inhibitors and autoimmune rheumatic diseases.
Benucci M; Bernardini P; Coccia C; De Luca R; Levani J; Economou A; Damiani A; Russo E; Amedei A; Guiducci S; Bartoloni E; Manfredi M; Grossi V; Infantino M; Perricone C
Autoimmun Rev; 2023 Apr; 22(4):103276. PubMed ID: 36649877
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous lupus erythematosus variants responsive to Janus kinase inhibition.
Ananthan L; Williams M; Morgan H; Patel GK
Dermatol Ther; 2022 Dec; 35(12):e15967. PubMed ID: 36346024
[No Abstract] [Full Text] [Related]
17. State-of-the-art treatment of systemic lupus erythematosus.
Tanaka Y
Int J Rheum Dis; 2020 Apr; 23(4):465-471. PubMed ID: 32134201
[TBL] [Abstract][Full Text] [Related]
18. Immunogenetics of cutaneous lupus erythematosus.
Hersh AO; Arkin LM; Prahalad S
Curr Opin Pediatr; 2016 Aug; 28(4):470-5. PubMed ID: 27386968
[TBL] [Abstract][Full Text] [Related]
19. [Cutaneous lupus erythematosus and skin manifestations in systemic lupus erythematosus].
Sticherling M
Z Rheumatol; 2013 Jun; 72(5):429-35. PubMed ID: 23743985
[TBL] [Abstract][Full Text] [Related]
20. [Antimalarials in lupus erythematosus treatment].
Woźniacka A
Przegl Lek; 2002; 59(3):179-82. PubMed ID: 12184034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
